Drug Information

Drug General Information
Drug ID
D0V5JH
Former ID
DIB013179
Drug Name
ALT-801
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 2 [531657]
Company
Altor bioscience
Target and Pathway
Target(s) Cellular tumor antigenp53 Target Info Immunomodulator (Immunostimulant) [531657]
KEGG Pathway MAPK signaling pathway
Sphingolipid signaling pathway
Cell cycle
p53 signaling pathway
PI3K-Akt signaling pathway
Apoptosis
Wnt signaling pathway
Neurotrophin signaling pathway
Thyroid hormone signaling pathway
Amyotrophic lateral sclerosis (ALS)
Huntington's disease
Hepatitis C
Hepatitis B
Measles
HTLV-I infection
Herpes simplex infection
Epstein-Barr virus infection
Pathways in cancer
Transcriptional misregulation in cancer
Viral carcinogenesis
Proteoglycans in cancer
MicroRNAs in cancer
Colorectal cancer
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Thyroid cancer
Basal cell carcinoma
Melanoma
Bladder cancer
Chronic myeloid leukemia
Small cell lung cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
NetPath Pathway FSH Signaling Pathway
PANTHER Pathway Apoptosis signaling pathway
Huntington disease
Wnt signaling pathway
p53 pathway
P53 pathway feedback loops 1
p53 pathway by glucose deprivation
p53 pathway feedback loops 2
Pathway Interaction Database Signaling events mediated by HDAC Class III
Validated targets of C-MYC transcriptional activation
LKB1 signaling events
Glucocorticoid receptor regulatory network
Direct p53 effectors
p75(NTR)-mediated signaling
AP-1 transcription factor network
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha
Signaling mediated by p38-alpha and p38-beta
Aurora A signaling
BARD1 signaling events
p53 pathway
PLK3 signaling events
Reactome Activation of NOXA and translocation to mitochondria
Activation of PUMA and translocation to mitochondria
Pre-NOTCH Transcription and Translation
Oxidative Stress Induced Senescence
Formation of Senescence-Associated Heterochromatin Foci (SAHF)
Oncogene Induced Senescence
DNA Damage/Telomere Stress Induced Senescence
Autodegradation of the E3 ubiquitin ligase COP1
TP53 Regulates Metabolic Genes
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Stabilization of p53
Factors involved in megakaryocyte development and platelet production
WikiPathways DNA Damage Response (only ATM dependent)
DNA Damage Response
ErbB Signaling Pathway
Senescence and Autophagy in Cancer
G1 to S cell cycle control
Sandbox Pathway
Wnt Signaling Pathway and Pluripotency
MAPK Signaling Pathway
TGF beta Signaling Pathway
Copper homeostasis
Bladder Cancer
Mammary gland development pathway - Involution (Stage 4 of 4)
Pre-NOTCH Expression and Processing
Apoptosis
ATM Signaling Pathway
Amyotrophic lateral sclerosis (ALS)
Retinoblastoma (RB) in Cancer
Spinal Cord Injury
Integrated Pancreatic Cancer Pathway
Oncostatin M Signaling Pathway
Gastric cancer network 2
Prostate Cancer
Signaling Pathways in Glioblastoma
Metastatic brain tumor
Alzheimers Disease
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Intrinsic Pathway for Apoptosis
Factors involved in megakaryocyte development and platelet production
Cell Cycle
Cell Cycle Checkpoints
Apoptosis Modulation and Signaling
Folate Metabolism
TP53 Network
Fluoropyrimidine Activity
miRNAs involved in DNA damage response
miRNA Regulation of DNA Damage Response
AMPK Signaling
References
Ref 531657Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
Ref 531657Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.